News & Insights

Join Jason Kolbert, Head of Research at D. Boral Capital and Prof. Joshua Brown, MD, PhD, CMIO of NRx Pharmaceuticals, to learn more about the clinical relevance of DCS in modern psychiatric care, the implications of improved formulation stability, and how this approach could fit within evolving treatment frameworks that include TMS, ketamine, and other rapid-acting antidepressants. We will also explore the potential for integration with NRx’s expanding clinic model and the broader commercial opportunity in treatment-resistant depression.

Citius Pharmaceuticals: From Development Stage to Commercial Oncology – A Live Discussion with CEO Leonard Mazur

Review this insightful fireside discussion with Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, and Jason Kolbert, Head of Research at D. Boral Capital. The conversation explores early LYMPHIR launch traction and physician adoption, alongside the company’s commercial execution strategy in a rare oncology market. The discussion also covers balance sheet positioning, portfolio expansion with Mino-Lok and Halo-Lido, and Citius’ path toward scaling revenue as a multi-asset commercial-stage company.

Beyond Air: Commercial Momentum and Global Expansion Driven by LungFit PH

Review this insightful fireside discussion with Steve Lisi, Chief Executive Officer of Beyond Air, Inc. (NASDAQ: XAIR), and Jason Kolbert, Head of Research at D. Boral Capital. The conversation highlights the company’s growing commercial foundation anchored by LungFit PH, including real-world hospital adoption, utilization trends, and the expanding role of nitric oxide delivery as a differentiated respiratory therapy platform.

Advancing Acute Psychiatric Care: Ketamine, Suicide Prevention, and a National Treatment Platform at NRx Pharmaceuticals

Review our in-depth fireside discussion with Jonathan C. Javitt, M.D., M.P.H., Founder, Chairman, Chief Scientist and CEO of NRx Pharmaceuticals, Inc., and Jason Kolbert, Head of Research at D. Boral Capital, focused on NRx’s evolving approach to acute psychiatric care and its strategy to address some of the most urgent unmet needs in mental health.

Reframing Alzheimer’s Drug Development: Clinical Signals, Regulatory Review, and the Path Forward for ANAVEX®2-73

Review our in-depth fireside chat with Anavex Life Sciences Corp. focused on its lead program, ANAVEX®2-73 (blarcamesine), and the evolving scientific and regulatory landscape surrounding early Alzheimer’s disease.

Transforming Critical Care: CytoSorbents’ Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review

This webinar discussion covers CytoSorb commercial momentum, the regulatory path for DrugSorb-ATR, the De Novo submission, and key financial milestones shaping CytoSorbents’ next phase of growth.

A New Wave in Neurodegeneration Treatment: How Clene’s CNS—Gold Nano-Particle Program (CNM-Au8®) Aims to Target Disease Progression in ALS, MS, and PD.

This fireside conversation between D. Boral Capital and Clene Nanomedicine reviews Clene’s CNS—Gold Nano-Particle (CNM-Au8®) program, the science behind targeting bioenergetic failure, and the company’s advancing work in ALS and other neurodegenerative diseases.

Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

This webinar explores recent breakthroughs in treatment approaches for inflammatory disease treatment, focusing on new clinical insights from Enlivex’s knee osteoarthritis program.